
News|Articles|December 5, 2012
FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks
The 32-mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
How California is rewriting the PBM playbook
3
New therapies on the way to lower Lp(a), a cardiovascular risk factor
4
Many inherited eye disease genes rarely cause vision loss, study found
5




















































